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Twenty-four years ago, I first had the privi-lege of working in a research  laboratory in dermatology for three years during medi-
cal school. It was my first exposure to immu-
nodermatology, and I marveled at the extent 
to which the molecular culprits of  various 
 immunologic diseases had been systematically 
identified and cataloged—especially given the 
rudimentary nature to which the molecular 
mechanisms of diseases in other physiologic 
systems and specialties had been worked out.
Since then, having subsequently spent 15 
years as a practicing clinician and 10 years 
concurrently as an investment professional, 
I have personally found it even more interest-
ing that none of those discoveries was really 
ever carried forward for the development of 
 targeted therapies. Having both witnessed and 
participated in the financing of companies 
whose business plans centered on treating rare 
diseases involving other organ systems—which 
were successful in both raising capital and 
developing treatments to help patients—the 
question that inevitably emerged was why did 
this phenomenon not happen with diseases in 
dermatology even though groundwork argu-
ably had been laid to a greater extent than for 
many of the conditions that ultimately ended 
up as the basis for companies? We have begun 
to see interest from investors and companies in 
developing treatments for a rare disease such as 
epidermolysis bullosa, but there are many other 
diseases within dermatology that remain unad-
dressed—some represented within the ranks of 
the patient groups making up the Coalition of 
Skin Diseases, but countless others that are not. 
Dermatology is indeed a specialty of a few 
very common afflictions, as well as many, 
many rare ailments, of which the aforemen-
tioned immunologic represent but a subset and 
for which the quality of research continues to 
advance and improve. Yet the focus of prod-
uct development remains squarely centered 
on those few common diseases, to the detri-
ment of the field. Many view dermatology as a 
medical specialty with few conditions affecting 
sufficient patient numbers to support a viable 
commercial enterprise; consequently, outside 
of those few entities, investment interest has 
historically been lukewarm. It seems almost 
necessary that, given the characteristics of the 
field, the orphan disease business model should 
be embraced as a means to both increase the 
breadth and depth of therapies within derma-
tology and reestablish the legitimacy of derma-
tology as a “serious” medical specialty.
The calculus to change the perception of 
investors has precedent and does not require 
extensive spreadsheet manipulation. Pioneered 
at Genzyme, which developed billion-dollar 
product franchises based on enzyme replace-
ment therapies for genetic diseases affecting a 
handful of patients, the orphan disease model 
posits that a scarcity of affected individuals 
need not make a disease less lucrative as com-
mercial opportunity. Indeed, it makes each of 
those individuals much more valuable and 
even more worthy of close attention and care. 
Annual courses of therapy cost not hundreds, 
but hundreds of thousands of dollars—and the 
regulatory exclusivity granted to such treat-
ments (Seven years’ worth in the United States 
and 10 years’ worth in Europe) because of the 
presumed limitations of their scope of util-
ity further buttresses this value. If suitably cho-
sen and priced accordingly, a company with a 
single drug for an indication with a prevalence 
of one to five cases per million can generate 
well over a billion dollars in sales or more. 
According to Thomson Reuters, almost a third 
of orphan drugs currently generate more than 
a billion dollars of sales in a year, with more 
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than $50 billion in global sales for the category. Moreover, 
there is always the potential for an unexpected upside from 
indications not previously considered at the time of initial 
development—both rituximab and recombinant erythropoi-
etin, now mainstays of therapy in several medical special-
ties and bellwethers of biotechnology drug development, 
started out as orphan drugs.
Of course, positing pie-in-the-sky scenarios on the back 
of an investor’s napkin does neglect certain real-world con-
siderations. The main requirement to achieve this rarefied 
status in the eyes of the regulatory agencies is simply the 
number of patients afflicted, but, of course, the social and 
commercial viability of such a model requires evidence that 
the investment in each patient is justified—that their lives 
are sufficiently transformed for the better to warrant the bur-
den of cost, both to government and private payers and to 
society as a whole. Such an undertaking will necessitate 
comprehensive efforts to provide validation of outcome 
measures and documentation of natural histories, similar to 
the work done by the International Dermatology Outcome 
Measures group for psoriasis and as has been the case with 
other conditions outside dermatology, such as muscular 
dystrophies.
It is ultimately this demonstration of value—showing that 
diseases of the skin are as functionally debilitating to the 
individuals who are unfortunate enough to have them as 
those found with other specialties—that is required to com-
pel reimbursement. If payers can be convinced to pony up 
for biologics costing tens of thousands of dollars a year for a 
condition as prevalent as psoriasis, then there is no reason 
why they cannot be swayed in similar fashion for treatments 
for isolated conditions within dermatology and at a higher 
per capita rate to make the rare disease business model fea-
sible—opening up a heretofore largely unexplored vista of 
value creation to attract investors and help patients, as well 
as improve the stature of dermatology within medicine and 
society as a whole.
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